Linda Wittkop
A5001041075- Hepatitis C virus research
- HIV/AIDS Research and Interventions
- HIV Research and Treatment
- Liver Disease Diagnosis and Treatment
- HIV/AIDS drug development and treatment
- HIV-related health complications and treatments
- Hepatitis B Virus Studies
- Liver Disease and Transplantation
- Cancer Cells and Metastasis
- Cancer Research and Treatments
- SARS-CoV-2 and COVID-19 Research
- Pneumocystis jirovecii pneumonia detection and treatment
- COVID-19 Clinical Research Studies
- Cannabis and Cannabinoid Research
- HIV, Drug Use, Sexual Risk
- Cytomegalovirus and herpesvirus research
- Viral-associated cancers and disorders
- Systemic Lupus Erythematosus Research
- Coffee research and impacts
- Bipolar Disorder and Treatment
- Immune Cell Function and Interaction
- Smoking Behavior and Cessation
- COVID-19 epidemiological studies
- Diet, Metabolism, and Disease
- Alcohol Consumption and Health Effects
Inserm
2016-2025
Université de Bordeaux
2016-2025
Bordeaux Population Health
2016-2025
Centre Hospitalier Universitaire de Bordeaux
2016-2025
Institut Bergonié
2022-2025
Santé Publique France
2017-2025
Institut national de recherche en informatique et en automatique
2017-2025
Institut de Recherche Vaccinale
2020-2024
Centre de Recherche Épidémiologie et Statistique
2024
Université Paris Cité
2018-2024
Objective Our aim was to prospectively assess the antibiotic resistance rates in Helicobacter pylori strains Europe 2018 and study link between consumption community H. levels different countries. Design The proportion of primary cases their corresponding risk factors were investigated 24 centres from 18 European countries according a standardised protocol. Data on collected for period 2008–2017. data assessed using generalised linear mixed models. model with best fit selected by means...
<h2>Summary</h2><h3>Background</h3> The life expectancy of people with HIV taking antiretroviral therapy (ART) has increased substantially over the past 25 years. Most previous studies were based on data from first few years after starting ART, when mortality is highest. However, many have been successfully treated ART for years, and up-to-date prognosis are needed. We aimed to estimate in adults at least 1 year Europe North America 2015 onwards. <h3>Methods</h3> used Antiretroviral Therapy...
Purpose: Gastric carcinomas are heterogeneous, and the current therapy remains essentially based on surgery with conventional chemotherapy radiotherapy. This study aimed to characterize biomarkers allowing detection of cancer stem cells (CSC) in human gastric carcinoma different histologic types.Experimental Design: The primary tumors from 37 patients intestinal- or diffuse-type noncardia were studied, patient-derived tumor xenograft (PDX) models immunodeficient mice developed. expressions...
Early initiation of combination antiretroviral therapy (cART), at higher CD4 cell counts, prevents disease progression and reduces sexual transmission human immunodeficiency virus (HIV). We describe the temporal trends in counts start cART adults from low-income, lower-middle-income, upper-middle-income, high-income countries (LICs, LMICs, UMICs, HICs, respectively).We included HIV-infected individuals aged ≥16 years who started between 2002 2015 a clinic participating International...
Abstract Effect estimates from randomized trials and observational studies might not be directly comparable because of differences in study design, other than randomization, data analysis. We propose a 3-step procedure to facilitate meaningful comparisons effect studies: 1) harmonization the protocols (eligibility criteria, treatment strategies, outcome, start end follow-up, causal contrast) so that target same effect, 2) analysis estimate 3) sensitivity analyses investigate impact...
Alcohol use is measured in diverse ways across settings. Harmonization of measures necessary to assess effects alcohol multi-cohort collaborations, such as studies people with HIV (PWH). Data were combined from 14 cohort (nine European, five North American) participating the Antiretroviral Therapy Cohort Collaboration. We analyzed data on adult PWH at any time 6 months before starting antiretroviral therapy. Five cohorts AUDIT-C and others used cohort-specific measures. harmonized grams/day,...
We investigated whether CD4:CD8 ratio and CD8 count were prognostic for all-cause, AIDS, non-AIDS mortality in virologically suppressed patients with high CD4 count.We used data from 13 European North American cohorts of human immunodeficiency virus-infected, antiretroviral therapy (ART)-naive adults who started ART during 1996-2010, followed the date they had ≥350 cells/μL (baseline). stratified Cox models to estimate unadjusted adjusted (for sex, people inject drugs, initiation year,...
Summary Background Hepatitis B virus (HBV)/hepatitis C (HCV) confection has been rarely studied in nonasian series. Aim To compare the characteristics of HBV/HCV coinfected patients to those HBV‐ or HCV‐monoinfected ANRS CO22 HEPATHER cohort study. Patients and Methods Of 20 936 included patients, 95 had HBV / HCV coinfection (hepatitis surface antigen, anti‐ antibody RNA positive) were matched with 375 ‐ 380 ‐monoinfected on age, gender time since diagnosis. Results F3‐F4 fibrosis was more...
BackgroundOur aim was to study the in vivo viral genetic pathways for resistance raltegravir, antiretroviral-experienced patients with virological failure (VF) on raltegravir-containing regimens.
We evaluated the impact of cytomegalovirus (CMV)–induced immune responses, autoimmune-induced and microbial translocation on activation in 191 human immunodeficiency virus type 1–infected patients from ANRS CO3 Aquitaine Cohort. All enrolled subjects had achieved long-term virological suppression during receipt combination antiretroviral therapy (cART). HLA-DR+/CD38+ expression was 16.8% among CD8+ T cells. Independent age, CD4+ T-cell count, 16S ribosomal DNA load, regulatory positive...
Background. Human immunodeficiency virus (HIV)/hepatitis C (HCV)–coinfected patients with cirrhosis have long been considered to be difficult treat, and real-life efficacy tolerance data all-oral direct-acting antiviral (DAA) combinations in these are scarce. Methods. Cirrhotic HIV/HCV-coinfected enrolled the French National Agency for Research on AIDS Viral Hepatitis (ANRS) CO13 HEPAVIH cohort initiating an DAA regimen were consecutively included. A negative HCV RNA result at 12 weeks of...
Objectives: We studied the link between T-cell activation, differentiation and senescence phenotypes non-AIDS-related comorbidities in HIV-suppressed patients. Design: Patients included ANRS CO3 Aquitaine Cohort were consecutively enrolled this cross-sectional study October 2011 May 2013 called Chronic Immune Activation Senescence (CIADIS) study. Methods: summarized immune markers [CD4+ CD8+ activation (DR+), (naive terminally differentiated memory T cells), (CD57+CD28-)] a weighted score by...
Background: The widespread introduction of combination antiretroviral therapy (cART) has increased survival HIV-infected patients. However, the prevalence age-related comorbidities remains higher than that general population, suggesting individuals with HIV suffer from accelerated aging. Immune activation, senescence and inflammation could play an important role in this process. Methods: CIADIS (Chronic Activation anD Senescence) sub-study analyzed biomarkers differentiation T cells a...
Broad direct-acting antiviral (DAA) access may reduce hepatitis C virus (HCV) incidence through a "treatment as prevention" (TasP) effect. We assessed changes in primary HCV following DAA among people living with HIV (PLHIV).
To assess the efficacy of inhaled ciclesonide in reducing risk adverse outcomes COVID-19 outpatients at developing severe illness.COVERAGE is an open-label, randomized controlled trial. Outpatients with documented COVID-19, factors for aggravation, symptoms ≤7 days, and absence criteria hospitalization are randomly allocated to either a control arm or one several experimental arms, including ciclesonide. The primary endpoint worsening (hospitalization, oxygen therapy home, death) by Day 14....
Objective: We aimed to determine the contribution of inflammasome activation in chronic low-grade systemic inflammation observed patients with HIV (PWH) on long-term suppressive antiretroviral therapy (ART) and explore mechanisms such activation. Design: Forty-two PWH ART (HIV-RNA < 40 copies/ml) were compared 10 HIV-negative healthy controls (HC). Methods: Inflammasome was measured by dosing mature interleukin (IL)-1β IL-18 cytokines patient serum. explored pathways through ex vivo...
We read with great interest the recent paper from Martín-Carmona et al., who found that HIV does not increase mortality risk after hepatitis C virus (HCV) cure direct-acting antivirals (DAA) in people advanced liver fibrosis [1].By publishing long-term followup data, authors provide valuable insights into unresolved question of whether or increases HCV cure.
Objective: People with HIV-HCV co-infection need antiretroviral treatment (ART) to suppress HIV and direct-acting antivirals (DAAs) cure HCV. ART is typically prioritized, but delays in DAA initiation may increase the risk of liver-related events HCV transmission others. Design: Target trial emulation observational data collected routine clinical practice from a collaboration cohorts Europe North America. Methods: We included DAA-naïve adults who achieved virologic suppression (HIV RNA<50...